184 related articles for article (PubMed ID: 19337632)
1. Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients.
Burz C; Berindan-Neagoe IB; Balacescu O; Tanaselia C; Ursu M; Gog A; Vlase L; Chintoanu M; Balacescu L; Leucuta SE; Irimie A; Cristea V
J Gastrointestin Liver Dis; 2009 Mar; 18(1):39-43. PubMed ID: 19337632
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters.
Burz C; Berindan-Neagoe I; Balacescu O; Todor N; Pelau D; Floares C; Kacso G; Tanaselia C; Ursu M; Vlase L; Leucuta SE; Cristea V; Irimie A
J BUON; 2010; 15(2):263-9. PubMed ID: 20658719
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.
Pectasides D; Pectasides M; Farmakis D; Gaglia A; Koumarianou A; Nikolaou M; Koumpou M; Kountourakis P; Papaxoinis G; Mitrou P; Economopoulos T; Raptis SA
Gynecol Oncol; 2004 Oct; 95(1):165-72. PubMed ID: 15385127
[TBL] [Abstract][Full Text] [Related]
4. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin pharmacokinetics during a four-hour infusion.
Kern W; Braess J; Böttger B; Kaufmann CC; Hiddemann W; Schleyer E
Clin Cancer Res; 1999 Apr; 5(4):761-5. PubMed ID: 10213210
[TBL] [Abstract][Full Text] [Related]
6. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer.
Chiara S; Nobile MT; Gozza A; Taveggia P; Heouaine A; Pastrone I; Percivale PL; Lionetto R; Sanguineti O; Rosso R
Anticancer Res; 2004; 24(1):355-60. PubMed ID: 15015621
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics of oxaliplatin: a critical review.
Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E
Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943
[TBL] [Abstract][Full Text] [Related]
9. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.
Gamelin E; Bouil AL; Boisdron-Celle M; Turcant A; Delva R; Cailleux A; Krikorian A; Brienza S; Cvitkovic E; Robert J; Larra F; Allain P
Clin Cancer Res; 1997 Jun; 3(6):891-9. PubMed ID: 9815764
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy.
Sundar S; Symonds RP; Decatris MP; Kumar DM; Osman A; Vasanthan S; O'byrne KJ
Gynecol Oncol; 2004 Aug; 94(2):502-8. PubMed ID: 15297195
[TBL] [Abstract][Full Text] [Related]
11. Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma.
Kallen KJ; Hofmann MA; Timm A; Gödderz W; Galle PR; Heike M
Z Gastroenterol; 2000 Feb; 38(2):153-7. PubMed ID: 10721170
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: a pilot investigation with preliminary results.
Merkel U; Wedding U; Roskos M; Höffken K; Hoffmann A
Exp Toxicol Pathol; 2003 Jun; 54(5-6):475-9. PubMed ID: 12877360
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
[TBL] [Abstract][Full Text] [Related]
14. Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis.
Watayo Y; Kuramochi H; Hayashi K; Nakajima G; Kamikozuru H; Yamamoto M
Jpn J Clin Oncol; 2010 Apr; 40(4):360-4. PubMed ID: 20085906
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
16. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
[TBL] [Abstract][Full Text] [Related]
17. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.
Petrioli R; Pascucci A; Francini E; Marsili S; Sciandivasci A; Tassi R; Civitelli S; Tanzini G; Lorenzi M; Francini G
Cancer Chemother Pharmacol; 2008 Jan; 61(1):105-11. PubMed ID: 17429632
[TBL] [Abstract][Full Text] [Related]
18. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
Oh SY; Kwon HC; Lee S; Lee DM; Yoo HS; Kim SH; Jang JS; Kim MC; Jeong JS; Kim HJ
Jpn J Clin Oncol; 2007 Dec; 37(12):930-5. PubMed ID: 18211984
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
